Rasagiline Mesylate

Description: Rasagiline mesylate (TVP-101; TV-1030, TVP-1022; Agn-1135; Azilect) is a potent, selective and irreversible MAO-B (monoamine oxidase B) inhibitor with the potential for the treatment of idiopathic PD/Parkinson's disease. It displays anti-Parkinsonian activity, and exhibits neuroprotective as well as antiapoptotic activity against several neurotoxins in cell culture. Rasagiline inhibits rat brain MAO type B and type A with IC50 of 4.43 nM and 412 nM, respectively. Rasagiline is three to 15 times more potent than selegiline for inhibition of MAO-B in rat brain and liver in vivo on acute and chronic administration, but has similar potency in vitro.

References: Br J Pharmacol. 2001 Jan; 132(2):500-6; Eur J Pharmacol. 1999 Feb 5; 366(2-3):127-35.

Related CAS:136236-51-6 (free base); 1216757-55-9 (Rasagiline 13C3 mesylate racemic); 185517-74-2 (S)-Rasagiline; 202464-88-8 (S)-Rasagiline mesylate; 1875-50-9 (racemic rasagiline); 136236-52-7 (tartrate); 161735-79-1 (mesylate);